Trials / Unknown
UnknownNCT05308875
Efficacy and Safety Evaluation of PD1-BCMA-CART
Clinical Study of the Safety and Efficacy of Non-viral Site-directed Integrated PD1-BCMA-CART in Adult Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial aims to evaluate the safety and efficacy of PD1-BCMA-CART in treating patients with relapsed or refractory multiple myeloma.
Detailed description
Using gene editing, chimeric antigen receptors recognizing BCMA were integrated into subject self-derived T cells to obtain a large number of BCMA-CART by in vitro amplification, and BCMA-CART back into the subjects could identify and kill myeloma cells in the subjects.This open-label, dose-escalation study was designed to evaluate the safety and antitumor efficacy of PD1-BCMA-CART in the treatment of relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PD1-BCMA-CART | Single infusion of PD1-BCMA-CART administered intravenously (i.v.) |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2025-01-01
- Completion
- 2025-10-01
- First posted
- 2022-04-04
- Last updated
- 2024-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05308875. Inclusion in this directory is not an endorsement.